ACUTUS MEDICAL INC (AFIB) Financials
Newest figures come from the 10-K for FY2024, filed Mar 24, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AFIB SEC filings page.
ACUTUS MEDICAL INC (AFIB) reported $20.2M in revenue for fiscal year 2024, up 181.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2024 brought positive gross profit, but thin margins and continued cash outflows mean financing remains central to operations.
Revenue more than doubled over the latest two reported years, while gross margin turned positive, indicating a meaningful improvement in selling economics. Operating cash flow improved from an outflow of$63.1M to an outflow of$31.7M , yet remained negative, so commercial progress has not become self-funding cash generation.
Liabilities exceeded assets in FY2024:
Capital spending was only
Financial Health Signals
ACUTUS MEDICAL INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
ACUTUS MEDICAL INC passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
ACUTUS MEDICAL INC reported a net loss of $9.5M while operations used $31.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
ACUTUS MEDICAL INC reported an operating loss of $57K against $5.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
ACUTUS MEDICAL INC generated $7.1M in revenue in Q4 2024. This represents an increase of 204.2% from the same quarter a year earlier. Against the prior quarter it is up 35.6%.
ACUTUS MEDICAL INC's EBITDA was -$73K in Q4 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 96.3% from the same quarter a year earlier. Against the prior quarter it is down 109.4%.
ACUTUS MEDICAL INC reported -$1.4M in net income in Q4 2024. This represents an increase of 95.8% from the same quarter a year earlier. Against the prior quarter it is up 74.9%.
ACUTUS MEDICAL INC earned -$0.05 per diluted share (EPS) in Q4 2024. This represents an increase of 95.7% from the same quarter a year earlier. Against the prior quarter it is up 73.7%.
Cash & Balance Sheet
ACUTUS MEDICAL INC recorded an outflow of $4.1M in free cash flow in Q4 2024, representing a cash shortfall after capex. This represents an increase of 78.4% from the same quarter a year earlier. Against the prior quarter it is down 10.6%.
ACUTUS MEDICAL INC held $14.0M in cash against $25.6M in long-term debt as of Q4 2024.
Not reported for Q4 2024.
Margins & Returns
ACUTUS MEDICAL INC's gross margin was 14.2% in Q4 2024, indicating the percentage of revenue retained after direct costs. This is up 21.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.1 percentage points.
ACUTUS MEDICAL INC's operating margin was -3.8% in Q4 2024, reflecting core business profitability. This is up 68.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 13.1 percentage points.
ACUTUS MEDICAL INC's net profit margin was -19.7% in Q4 2024, showing the share of revenue converted to profit. No change is given against Q4 2023: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q4 2024.
Capital Allocation
ACUTUS MEDICAL INC reported no research and development spending in Q4 2024. This represents a decrease of 100.0% from the same quarter a year earlier.
ACUTUS MEDICAL INC invested $36K in capex in Q4 2024, funding long-term assets and infrastructure. This represents a decrease of 96.3% from the same quarter a year earlier. Against the prior quarter it is up 620.0%.
Not reported for Q4 2024.
AFIB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.1M+204.2% | $5.3M+155.6% | $4.1M+172.4% | $3.6M+191.9% | $2.3M | $2.1M-43.5% | $1.5M-62.8% | $1.2M-66.3% |
| Cost of Revenue | $6.1M+143.7% | $4.9M+55.4% | $4.5M+76.9% | $3.7M+73.1% | $2.5M | $3.1M-54.7% | $2.5M-73.9% | $2.1M-69.6% |
| Gross Profit | $1.0M+710.8% | $372K+134.1% | -$343K+66.1% | -$30K+96.5% | -$166K | -$1.1M+67.0% | -$1.0M+82.0% | -$869K+73.3% |
| R&D Expenses | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $731K | $896K-84.9% | $917K-88.4% | $938K-88.3% |
| SG&A Expenses | $2.6M-35.5% | $2.3M-1.5% | $2.2M-32.2% | $3.3M-25.4% | $4.0M | $2.4M-75.7% | $3.3M-76.8% | $4.5M-68.9% |
| Operating Income | -$272K+84.0% | $489K+128.9% | $301K+109.8% | -$575K+89.1% | -$1.7M | -$1.7M+91.7% | -$3.1M-120.5% | -$5.3M+86.4% |
| EBITDA | -$73K+96.3% | $773K+163.5% | $581K+121.6% | -$311K+93.7% | -$2.0M | -$1.2M+93.5% | -$2.7M-115.9% | -$5.0M+86.5% |
| Interest Expense | $1.4M-10.9% | $1.4M-1.0% | $1.5M+8.2% | $1.5M+13.1% | $1.5M | $1.4M+27.1% | $1.4M+8.1% | $1.3M-7.4% |
| Income Tax | N/A | N/A | N/A | $0 | -$12K | $75K | $0 | $0 |
| Net Income | -$1.4M+95.8% | -$5.6M+57.6% | -$914K+95.0% | -$1.6M+90.1% | -$33.8M | -$13.2M+35.2% | -$18.3M-420.8% | -$16.3M+59.2% |
| EPS (Basic) | -$0.05+95.7% | -$0.19+57.8% | -$0.03+95.2% | -$0.06+89.5% | -$1.16-318.9% | -$0.45+37.5% | -$0.63-493.8% | -$0.57+59.9% |
| EPS (Diluted) | -$0.05+95.7% | -$0.19+57.8% | -$0.03+95.2% | -$0.06+89.5% | -$1.16-318.9% | -$0.45+37.5% | -$0.63-493.8% | -$0.57+59.9% |
| Diluted Shares (Avg) | N/A | 30M+1.8% | 30M+2.3% | 30M+3.2% | N/A | 29M+3.2% | 29M+2.4% | 29M+2.3% |
AFIB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $28.6M-46.9% | $32.2M-62.0% | $35.5M-64.6% | $41.7M-64.1% | $54.0M-59.6% | $84.7M-26.1% | $100.3M-27.5% | $116.0M-11.9% |
| Current Assets | $25.6M-44.7% | $27.2M-62.6% | $28.5M-67.4% | $34.4M-66.2% | $46.3M-60.8% | $72.6M-22.6% | $87.3M-24.8% | $101.8M-2.5% |
| Cash & Equivalents | $14.0M-26.9% | $12.6M-47.7% | $13.3M-42.2% | $18.5M-18.8% | $19.2M-25.1% | $24.1M-13.9% | $23.1M-50.5% | $22.7M+84.6% |
| Short-Term Investments | $0-100.0% | $0-100.0% | $0-100.0% | $1.5M-96.8% | $3.2M-92.8% | $14.4M-62.5% | $31.5M-25.8% | $46.8M-24.8% |
| Inventory | $1.8M-58.2% | $4.2M-73.4% | $5.2M-66.7% | $5.9M-60.6% | $4.3M+138.5% | $15.7M+7.8% | $15.7M+2.4% | $14.9M-15.2% |
| Accounts Receivable | $7.9M-30.6% | $10.0M+11.4% | $9.2M+20.4% | $7.8M+45.1% | $11.4M-36.6% | $9.0M+178.6% | $7.7M+195.5% | $5.3M+79.3% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0-100.0% |
| Total Liabilities | $40.2M-26.6% | $42.5M-19.9% | $40.3M-28.8% | $45.7M-17.7% | $54.8M-6.1% | $53.0M-6.7% | $56.6M-8.3% | $55.5M-11.7% |
| Current Liabilities | $12.4M-34.3% | $14.7M-0.7% | $12.4M-32.1% | $9.9M-42.3% | $18.9M-4.7% | $14.8M-19.4% | $18.2M-19.8% | $17.1M-1.2% |
| Non-Current Liabilities | $27.8M-22.6% | $27.8M-27.3% | $27.9M-27.2% | $35.8M-6.8% | $35.9M-6.9% | $38.3M-0.7% | $38.3M-1.6% | $38.4M-15.7% |
| Long-Term Debt | $25.6M-21.7% | $25.3M-27.3% | $25.1M-27.4% | $32.8M-5.0% | $32.7M-5.2% | $34.8M+1.3% | $34.6M+1.3% | $34.5M-15.4% |
| Total Equity | -$11.6M-1218.8% | -$10.3M-132.5% | -$4.8M-111.0% | -$4.0M-106.6% | -$879K-101.2% | $31.7M-45.1% | $43.7M-42.9% | $60.5M-12.1% |
| Retained Earnings | -$609.5M-1.6% | -$608.1M-7.4% | -$602.5M-9.0% | -$601.6M-12.5% | -$600.0M-15.8% | -$566.2M-6.1% | -$553.0M-7.8% | -$534.6M-3.1% |
Not reported in any period shown, so not listed: Goodwill.
AFIB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.1M+77.5% | -$3.7M+73.6% | -$7.0M+54.6% | -$16.9M-7.6% | -$18.0M-6.8% | -$14.0M+34.4% | -$15.4M+33.5% | -$15.7M+43.0% |
| Depreciation & Amortization | $250K+244.5% | $284K-40.1% | $280K-25.3% | $264K-14.0% | -$173K+96.0% | $474K-73.1% | $375K-80.9% | $307K-83.7% |
| Stock-Based Compensation | N/A | $128K-90.0% | $49K-97.2% | $202K-65.5% | N/A | $1.3M-32.2% | $1.7M-32.8% | $586K-80.7% |
| Capital Expenditures | -$36K-96.3% | $5K-98.8% | $38K-94.9% | $105K+320.0% | -$968K-56.9% | $410K-45.7% | $752K+19.4% | $25K-97.7% |
| Free Cash Flow | -$4.1M+78.4% | -$3.7M+74.3% | -$7.0M+56.5% | -$17.0M-8.1% | -$19.0M+0.7% | -$14.4M+34.8% | -$16.1M+32.1% | -$15.8M+45.1% |
| Investing Cash Flow | $5.5M-51.2% | $3.0M-82.4% | $4.5M-70.5% | $9.2M-39.5% | $11.2M-8.2% | $16.9M+403.7% | $15.1M-79.3% | $15.2M-4.7% |
| Financing Cash Flow | -$225K+54.5% | $0+100.0% | -$2.6M-12395.2% | -$42K+80.3% | -$495K-202.1% | -$1.9M-322.5% | -$21K+99.8% | -$213K-407.1% |
| Share Buybacks | N/A | $0-100.0% | N/A | N/A | -$35K-28.6% | $12K-29.4% | -$194K+331.1% | $217K |
Not reported in any period shown, so not listed: Dividends Paid.
AFIB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 14.2%+21.3pp | 7.1%+60.0pp | -8.3%+58.5pp | -0.8%+69.1pp | -7.1% | -52.9%+37.8pp | -66.8% | -70.0%+18.6pp |
| Operating Margin | -3.8%+68.8pp | 9.3%+91.4pp | 7.3% | -15.9% | -72.6% | -82.1% | -202.0% | -424.5% |
| Net Margin | -19.7% | -106.5% | -22.1% | -44.7% | -1438.7% | -642.6% | -1211.0% | -1313.6% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | -41.8%-6.4pp | -41.9%-49.4pp | -27.0%+31.2pp |
| Return on Assets | -4.9%+57.7pp | -17.4%-1.8pp | -2.6%+15.7pp | -3.9%+10.2pp | -62.6% | -15.6%+2.2pp | -18.3%-22.4pp | -14.1%+16.3pp |
| Current Ratio | 2.06-0.4x | 1.85-3.1x | 2.30-2.5x | 3.48-2.5x | 2.44-3.5x | 4.92-0.2x | 4.79-0.3x | 5.95-0.1x |
| Debt-to-Equity | N/A | N/A | N/A | N/A | N/A | 1.10+0.5x | 0.79+0.3x | 0.570.0x |
| Asset Turnover | 0.25+0.2x | 0.16+0.1x | 0.12+0.1x | 0.09+0.1x | 0.04 | 0.020.0x | 0.020.0x | 0.010.0x |
| FCF Margin | -57.4% | -70.3% | -169.9% | -469.9% | -808.7% | -699.9% | -1064.1% | -1268.4% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$11.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| ACUTUS MEDICAL INC AFIB | FY2024 | $20.2M | -$9.5M | -47.4% | N/A | — |
| GUIDED THERAPEUTCS INC GTHP | FY2025 | $767K | -$3.2M | N/A | $18.3M | — |
| IR-MED INC IRME | FY2024 | N/A | N/A | N/A | $231K | — |
Where ACUTUS MEDICAL INC Ranks
Frequently Asked Questions
What is ACUTUS MEDICAL INC's annual revenue?
ACUTUS MEDICAL INC (AFIB) reported $20.2M in total revenue for fiscal year 2024. This represents a 181.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is ACUTUS MEDICAL INC's revenue growing?
ACUTUS MEDICAL INC (AFIB) revenue grew by 181.4% year-over-year, from $7.2M to $20.2M in fiscal year 2024.
Is ACUTUS MEDICAL INC profitable?
No, ACUTUS MEDICAL INC (AFIB) reported a net income of -$9.5M in fiscal year 2024, with a net profit margin of -47.4%.
What is ACUTUS MEDICAL INC's EBITDA?
ACUTUS MEDICAL INC (AFIB) had EBITDA of $970K in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does ACUTUS MEDICAL INC have?
As of fiscal year 2024, ACUTUS MEDICAL INC (AFIB) had $14.0M in cash and equivalents against $25.6M in long-term debt.
What is ACUTUS MEDICAL INC's gross margin?
ACUTUS MEDICAL INC (AFIB) had a gross margin of 5.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is ACUTUS MEDICAL INC's operating margin?
ACUTUS MEDICAL INC (AFIB) had an operating margin of -0.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is ACUTUS MEDICAL INC's net profit margin?
ACUTUS MEDICAL INC (AFIB) had a net profit margin of -47.4% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is ACUTUS MEDICAL INC's free cash flow?
ACUTUS MEDICAL INC (AFIB) recorded an outflow of $31.8M in free cash flow during fiscal year 2024. This represents a 49.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is ACUTUS MEDICAL INC's operating cash flow?
ACUTUS MEDICAL INC (AFIB) recorded an outflow of $31.7M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are ACUTUS MEDICAL INC's total assets?
ACUTUS MEDICAL INC (AFIB) had $28.6M in total assets as of fiscal year 2024, including both current and long-term assets.
What are ACUTUS MEDICAL INC's capital expenditures?
ACUTUS MEDICAL INC (AFIB) invested $112K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
What is ACUTUS MEDICAL INC's current ratio?
ACUTUS MEDICAL INC (AFIB) had a current ratio of 2.06 as of fiscal year 2024, which is generally considered healthy.
What is ACUTUS MEDICAL INC's return on assets (ROA)?
ACUTUS MEDICAL INC (AFIB) had a return on assets of -33.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
How does ACUTUS MEDICAL INC's liquidity compare with its operating cash outflow?
At the end of fiscal year 2024, ACUTUS MEDICAL INC (AFIB) held $14.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $31.7M over that year. Dividing the one by the other, the reported balance equals about 5 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is ACUTUS MEDICAL INC's debt-to-equity ratio negative or not reported?
ACUTUS MEDICAL INC (AFIB) has negative shareholder equity of -$11.6M as of fiscal year 2024, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is ACUTUS MEDICAL INC's Piotroski F-Score?
ACUTUS MEDICAL INC (AFIB) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are ACUTUS MEDICAL INC's earnings high quality?
ACUTUS MEDICAL INC (AFIB) reported a net loss of $9.5M while operations used $31.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can ACUTUS MEDICAL INC cover its interest payments?
ACUTUS MEDICAL INC (AFIB) reported an operating loss of $57K against $5.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.